Article
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
British journal of cancer - 1 Sept 2022
Uutela Aki, Osterlund Emerik, Halonen Päivi, Kallio Raija, Ålgars Annika, Salminen Tapio, Lamminmäki Annamarja, Soveri Leena-Maija, Ristamäki Raija, Lehtomäki Kaisa, Stedt Hanna, Heervä Eetu, Muhonen Timo, Kononen Juha, Nordin Arno, Ovissi Ali, Kytölä Soili, Keinänen Mauri, Sundström Jari, Nieminen Lasse, Mäkinen Markus J, Kuopio Teijo, Ristimäki Ari, Isoniemi Helena, Osterlund Pia
Abstract excerpt
BACKGROUND: Outcomes after metastasectomy for metastatic colorectal cancer (mCRC) vary with RAS and BRAF mutational status, but their effects on resectability and conversion rates have not been extensively studied. METHODS: This substudy of the prospective RAXO trial included 906 patients recruited between 2011 and 2018. We evaluated repeated centralised resectability assessment, conversion/resection rates and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
